Nuvisan GmbH

Nuvisan GmbH is conducting studies that focus on cardiovascular diseases, with particular attention to the rare kidney disorder Alport syndrome. The trials aim to evaluate the safety profile of emerging therapies and understand their impact on heart‑related outcomes.

• Safety and tolerability assessments in healthy volunteers
• Monitoring of cardiac biomarkers and vascular function
• Exploration of disease‑modifying potential in Alport syndrome

The research is driven by a dedicated investigator team at the Gauting campus, supporting Nuvisan’s commercial pipeline in Europe.

In the realm of nervous system diseases, the site is evaluating a novel candidate for the treatment of migraine. The purpose of the work is to determine therapeutic efficacy and establish optimal dosing strategies for acute headache relief.

• Dose‑finding and response evaluation
• Tracking of headache frequency and severity
• Collection of patient‑reported outcome measures

With a single experienced investigator, the clinic leverages its expertise in neurological disorders to advance innovative migraine solutions.

The facility also runs investigations centered on pharmacokinetics and drug disposition, exemplified by studies of inhaled and intravenous LASAG formulations in healthy adults. These trials seek to map how the compound is absorbed, distributed, metabolized, and eliminated, while confirming safety.

• Single‑dose pharmacokinetic profiling
• Comparison of inhaled versus intravenous administration
• Safety monitoring and adverse event reporting

Conducted under an open‑label, two‑part design, the research supports Nuvisan’s broader drug development program across Europe.